Gemini Genomics Appoints MC Sullivan as Executive Vice President of Corporate Communications and Bioethics.

Biotechnology/Health Editors

BIOWIRE2K

CAMBRIDGE, U.K.--(BW HealthWire)--Jan. 24, 2001

Gemini Genomics plc (Nasdaq: GMNI) today announced that M.C. Sullivan has joined Gemini Genomics as Executive Vice President of Corporate Communications and Bioethics. Ms. Sullivan had previously consulted for Gemini on ethical standards and practices in all areas of Gemini's clinical and research activities. Ms. Sullivan is an attorney and an ethicist who is an internationally recognized authority in the field of bioethics.

Ms. Sullivan most recently served as the executive vice president of Midwest Bioethics Center, a private consulting and educational agency specializing in health care ethics and law, based in Kansas City, MO. Prior to joining Midwest Bioethics Center in 1996, Sullivan was an independent consultant providing education and consultation in health care ethics and law to health care professionals and institutions and has been Associate Dean at the University of Southern Europe in Monaco. In her previous positions, Ms. Sullivan served as spokesperson for these organizations and has worked extensively with the print and broadcast media. In addition, she has published extensively and is a well-known speaker to health care, legal and bioethics audiences.

Ms. Sullivan holds a Juris Doctor degree from the Massachusetts School of Law, as well as a master of theological studies degree in ethics from Harvard University. She graduated from Newton-Wellesley Hospital School of Nursing and holds a bachelor of arts degree in philosophy from Emmanuel College. Ms. Sullivan serves on the Board of Directors of the American Society of Law, Medicine, and Ethics and is a Kornfeld Fellow for 2000-2001.

"Ms. Sullivan's presence on our executive management team is a further indication of the pre-eminent role that Gemini gives to the integration of bioethics into its strategic agenda.", stated Paul Kelly MD, President and Chief Executive Officer of Gemini Genomics. "By combining the areas of corporate communications and bioethics, we incorporate ethical concerns and principles into our decision-making processes and policies and demonstrate that we are very mindful of the sensitivities that surround the public's understanding of genetic research. Gemini has always adhered to the strictest bioethical standards and continues to do so."

Gemini is a clinical genomics company focused on the discovery and commercialization of novel gene-based targets. Gemini's approach integrates comprehensive clinical data and detailed genetic information from a wide range of human population groups, including twins, disease affected families, isolated (founder) populations and drug trial subjects. By investing in leading edge bioinformatics technologies, Gemini is able to effectively apply these resources to the acceleration of disease gene identification, target discovery, and drug development. Gemini aims to maximize revenue generation arising from the commercialization of its discoveries by retaining control over the gene discovery process and taking advantage of the greater potential value offered by later-stage licensing opportunities. The Company has offices in the United States, United Kingdom, Sweden and Canada. For more information about Gemini Genomics, visit the company's website, www.gemini-genomics.com.

Except for the historical information presented, certain matters discussed in this press release are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development including statements regarding the Company's clinical development programs, the expected timing of clinical trials and regulatory filings. Other risks and uncertainties include discovering and developing the potential application based on gene associations and developing increased understanding of complex disorders. Such statements are based on management's current expectations, but actual results may differ materially.